Literature DB >> 23016526

Human T-cell lymphotropic virus in patients infected with HIV-1: molecular epidemiology and risk factors for transmission in Piaui, Northeastern Brazil.

Evaldo H de Oliveira1, Aldemir B Oliveira-Filho, Lucinda A Souza, Letiano V da Silva, Marluísa O G Ishak, Ricardo Ishak, Antonio C R Vallinoto.   

Abstract

This study aimed to describe the epidemiological, immunological and molecular features of infection by the human T-lymphotropic virus-1/2 (HTLV-1/2) in individuals with HIV-1 in an urban area of Piaui State, Brazil. Exclusion criteria included patients under 18 years of age, pregnant women or Amerindians. Of 805 individuals analyzed by the serological method (ELISA) for the detection of anti-HTLV-1/2, 18 (2.24%) were positive, but only 13 (1.61%) were confirmed by PCR. The RFLP analysis revealed that nine (1.12%) of these subjects were positive for HTLV-1 and four (0.5%) for HTLV-2. The mean age of these co-infected individuals was 50.9±9.1 years, and a significant association was found with age (above 40 years: p = 0.002), minor surgeries (p = 0.004) and blood transfusion (p = 0.031). Quantification of the T CD4+/CD8+ lymphocytes and the HIV-1 viral load showed no significant association of T CD8 + lymphocyte levels with co-infection in the patients with HIV-1/HTLV-1. The sequencing of the LTR region and phylogenetic analysis indicated that the nine HTLV-1 strains belong to the Transcontinental subgroup of the Cosmopolitan group (1a), with a 83% (neighbor-joining) bootstrap value. The HTLV-2 strains were identified as subtype HTLV-2c, supported by a bootstrap value of 79%. Further studies in other population subgroups, such as blood donors and drug users, will be necessary to clarify the dissemination of HTLV-1/2 in Piau and elucidate the developmental profile of the virus in the region.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23016526     DOI: 10.2174/1570162x11209080700

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  12 in total

1.  Spread of Human T-Lymphotropic Virus 1 and 2 Among Relatives of People Who Use Illicit Drugs in Northern Brazil.

Authors:  Aldemir Branco Oliveira-Filho; Paula Cristina Rodrigues Frade; Ricardo Roberto de Souza Fonseca; Leila Sawada; Luísa Caricio Martins; Luiz Fernando Almeida Machado; Antonio Carlos Rosário Vallinoto; Ricardo Ishak; José Alexandre Rodrigues de Lemos; Benedikt Fischer; Emil Kupek
Journal:  Front Microbiol       Date:  2022-06-03       Impact factor: 6.064

2.  Human T cell lymphotropic virus type 2a strains among HIV type 1-coinfected patients from Brazil have originated mostly from Brazilian Amerindians.

Authors:  Mariana Cavalheiro Magri; Luis Fernando de Macedo Brigido; Helena Kaminami Morimoto; Adele Caterino-de-Araujo
Journal:  AIDS Res Hum Retroviruses       Date:  2013-04-11       Impact factor: 2.205

Review 3.  HTLV-1, the Other Pathogenic Yet Neglected Human Retrovirus: From Transmission to Therapeutic Treatment.

Authors:  Nicolas Futsch; Renaud Mahieux; Hélène Dutartre
Journal:  Viruses       Date:  2017-12-21       Impact factor: 5.048

4.  Human T-lymphotropic virus 1 and 2 among people who used illicit drugs in the state of Pará, northern Brazil.

Authors:  Aldemir B Oliveira-Filho; Ana Paula S Araújo; Andreia Polliana C Souza; Camila M Gomes; Gláucia C Silva-Oliveira; Luísa C Martins; Benedikt Fischer; Luiz Fernando A Machado; Antonio Carlos R Vallinoto; Ricardo Ishak; José Alexandre R Lemos; Emil Kupek
Journal:  Sci Rep       Date:  2019-10-14       Impact factor: 4.379

5.  Distribution of Human Immunodeficiency Virus and Human T-Leukemia Virus Co-infection in Bahia, Brazil.

Authors:  Felicidade Mota Pereira; Fred Luciano Neves Santos; Ângelo Antônio Oliveira Silva; Nathan Menezes Nascimento; Maria da Conceição Chagas Almeida; Roberto Perez Carreiro; Bernardo Galvão-Castro; Maria Fernanda Rios Grassi
Journal:  Front Med (Lausanne)       Date:  2022-01-10

Review 6.  The Epidemiological Impact of STIs among General and Vulnerable Populations of the Amazon Region of Brazil: 30 years of Surveillance.

Authors:  Luiz Fernando Almeida Machado; Ricardo Roberto de Souza Fonseca; Maria Alice Freitas Queiroz; Aldemir Branco Oliveira-Filho; Izaura Maria Vieira Cayres-Vallinoto; Antonio Carlos Rosário Vallinoto; Marluísa de Oliveira Guimarães Ishak; Ricardo Ishak
Journal:  Viruses       Date:  2021-05-07       Impact factor: 5.048

7.  Prevalence and genetic characterisation of HTLV-1 and 2 dual infections in patients with pulmonary tuberculosis in Central-West Brazil.

Authors:  Aline Garcia Kozlowski; Megmar Aparecida dos Santos Carneiro; Márcia Alves Dias de Matos; Sheila Araújo Teles; João Alves Filho Araújo; Koko Otsuki; Ana Carolina Paulo Vicente; Regina Maria Bringel Martins
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-10-09       Impact factor: 2.743

8.  SEROPREVALENCE OF HTLV IN A POPULATION OF HIV1-INFECTED PATIENTS IN MIDWESTERN BRAZIL.

Authors:  Aline Garcia Kozlowski; Márcia Alves Dias de Matos; Megmar Aparecida Dos Santos Carneiro; Carmen Luci Rodrigues Lopes; Sheila Araújo Teles; Carolina Paulo Vicente; Regina Maria Bringel Martins
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2016-11-03       Impact factor: 1.846

9.  HTLV-1/2 prevalence in two Amazonian communities.

Authors:  Elida Cg Mata; Roberto M Bezerra; Aldo A Proietti Júnior; Luana Ks Pamplona; Lilian O Gomes; Valmir C Corrêa; Jordan Sr Caluff; Geanny S Borges; J Casseb; Lib Kanzaki
Journal:  J Virus Erad       Date:  2018-07-01

10.  Prevalence and Molecular Epidemiology of Human T-Lymphotropic Virus (HTLV) Infection in People Living With HIV/AIDS in the Pará State, Amazon Region of Brazil.

Authors:  Samira Peixoto Alencar; Marlinda de Carvalho Souza; Ricardo Roberto de Souza Fonseca; Cláudia Ribeiro Menezes; Vânia Nakauth Azevedo; Andre Luis Ribeiro Ribeiro; Sandra Souza Lima; Rogério Valois Laurentino; Maria Dos Anjos de Abreu Pina Barbosa; Felipe Bonfim Freitas; Aldemir Branco Oliveira-Filho; Luiz Fernando Almeida Machado
Journal:  Front Microbiol       Date:  2020-10-22       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.